INS and type 2 diabetes mellitus: In 795 adults with type 2 diabetes naïve to insulin therapy, efsitora again achieved non-inferior HbA1c reduction (-1.19% vs. -1.16%; between-group difference -0.03%, 95% CI -0.18 to 0.12) at 52 weeks, but with fewer clinically significant or severe hypoglycemia episodes (0.50 vs. 0.88 events/person-year; rate ratio 0.57, 95% CI 0.39 to 0.84).